JPMorgan ceases to be a substantial holder of Medibank: Medibank stock has 9 ratings

Published on 10/02/2026 at 04:10 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Fiscal 2026 revenue reached AUD 9.12 billion, up 5.90 percent. Medibank stock has 9 ratings and an AUD 5.00 average target.

Medibank, AU000000MPL3, Illustration mit AI erstellt.

Medibank Private Limited (ISIN AU000000MPL3) reported operating profit of AUD 813.5 million for fiscal year 2026, up 6.70 percent from the prior year. On September 22, 2026, MarketScreener reported that JPMorgan Chase ceased to be a substantial holder of Medibank. The ownership change adds a fresh market detail to a company picture shaped by expanding health services.

Ownership changes after results

The JPMorgan disclosure followed Medibank's fiscal 2026 results and arrived as the company continued to broaden its role beyond private health insurance. The business operates through health insurance and Medibank Health, with the latter covering primary care, home services and virtual care.

Medical Republic reported on September 16, 2026, that Medibank Health revenue rose 30.80 percent to AUD 634.8 million in fiscal year 2026. Segment profit increased 31.30 percent to AUD 100.7 million, including AUD 6.2 million from Better Medical.

Health services set the growth pace

The growth mix is important because the core insurance operation expanded more slowly. Health insurance revenue increased 4.60 percent to AUD 8.59 billion in fiscal year 2026, while health insurance operating profit rose 3.80 percent to AUD 769.8 million.

Medibank's primary care network reached 169 clinics, and GP consultations increased 26.70 percent to 4.1 million in fiscal year 2026, according to Medical Republic. The company is targeting 7 million annual consultations by fiscal year 2028, making healthcare delivery a measurable second growth engine beside insurance.

Analysts see AUD 5.00 target

Investing.com lists 9 analyst ratings, with 1 Buy, 8 Holds and 0 Sells, alongside an average 12-month target of AUD 5.00. The consensus is a neutral signal, while the operating figures show that Medibank Health is growing faster than the established insurance segment.

Investing.com also lists December 1, 2026, as the next earnings date. The scheduled report will give investors a new test of health services growth, insurance margins and the cost pressures affecting policyholder mix.

ASX quote and Lang & Schwarz reference

Medibank's ASX quote stood at AUD 4.53 on October 1, 2026, versus an AUD 4.62 prior close. The dormant Lang & Schwarz snapshot carried a prior close of EUR 2.78 for September 30, 2026; no current intraday euro quote is stated here.